Churchill Capital Corp XI

can, as we've learned more and more about how to work with a brand new high science product like Tavneos in this current environment. The other side is on the patient side. And, you know, again, using hopefully appropriate ways, not hopefully, but definitely using appropriate methods, we'd love to be able to help patients have better, more thorough conversations with their healthcare practitioners about the properties of tabneus, the data, and what it might mean for their particular condition. These are really motivated patients in the ANCA world. They haven't always had much to organize around, frankly, so we're hoping that we can help them, again, with appropriate educational access about not just their disease, but the mechanism of action of this drug, and again, how they might have intelligent conversations with their doctors about what this drug may or may not mean in their particular case. So that's something we're working on very much. And then I guess finally, peer-to-peer discussions, especially in and around major conferences to the extent that, again, we can appropriately encourage those or make those forums available to allow peers to talk to each other about their experience with Dabnios today. I think that's going to be very powerful. because many of those anecdotes are extremely interesting, extremely moving, and I'm hoping we'll start hearing a lot more of that at upcoming meetings like European Renal Association, at ULAR, and then, of course, a little later on at ACR and ASN here in the United States. But access and education, both on the physician and patient side, I think those are big levers.

Okay, and what are you hearing about, I guess, from your sales organization in terms of, I guess, the key areas of pushback and the areas that you're having to do, I guess, the most work to educate physicians around for starting tabneos, either that, I guess, first to getting that first prescription?

Yeah, that's a really good question. So, in general... The good news is that physicians are very quick to pick up the Tabneos, what I call therapeutic value proposition, right? So that's important because they do realize, and I think the awareness of what we showed in the advocate trial is fairly high. Not perfect yet. There's still a lot of questions around glucocorticoid use and how to start Tabneos. And the answer is, if you have a patient... that fulfills the description on the label with active severe disease, you start them right away. You don't have to do anything else with, you know, bells and whistles around the background therapy you use. That's whatever the background therapy is you deem appropriate for that patient. So that's been a set of questions, and those have been very good discussions. Many discussions early on surrounded accessing the medication. How do I start tab meows? How do I get it? How long do I use it? Again, those have been very productive discussions. And more and more, the medical part of that discussion is happening peer-to-peer, which is wonderful. So I think that those are the kinds of things we were looking at early on. We got a lot of very important and productive input. We've acted on that input, and I believe fundamentally the path to getting the medication to the appropriate patients has become a lot easier, and physicians are understanding more and more that they have a great deal of discretion in how to start tabneos, but the answer is they don't really have to wait. If they have a patient that fits the label, they can get tabneos on them right away.